{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:44:29Z","timestamp":1786146269367,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clbc.2026.06.011","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:24:13Z","timestamp":1782401053000},"page":"72-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Axillary Management After Neoadjuvant Endocrine Therapy in HR-Positive\/HER2-Negative Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Zhangqi","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8175-0513","authenticated-orcid":false,"given":"Weifeng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.06.011_bib0001","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2026.06.011_bib0002","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.bjc.6605845","article-title":"Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool","volume":"103","author":"Chia","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2026.06.011_bib0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/cncr.22789","article-title":"Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer","volume":"110","author":"Semiglazov","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2026.06.011_bib0004","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1023\/A:1013128213451","article-title":"Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0005","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cncr.21872","article-title":"Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the PROACT trial","volume":"106","author":"Cataliotti","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2026.06.011_bib0006","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both: the IMPACT trial","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0007","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","article-title":"Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane: ACOSOG Z1031","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0008","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamaoncol.2021.2132","article-title":"Neoadjuvant endocrine therapy in clinical practice: a review","volume":"7","author":"Sella","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040902","article-title":"Neoadjuvant endocrine therapy in breast cancer management: state of the art","volume":"13","author":"Lerebours","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.06.011_bib0010","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0011","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2026.06.011_bib0012","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0013","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1200\/JCO-25-00099","article-title":"Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0014","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1245\/s10434-019-07785-y","article-title":"Patterns of axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach","volume":"26","author":"Weiss","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0015","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1245\/s10434-020-08905-9","article-title":"Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer: systematic literature review and NCDB analysis","volume":"27","author":"Stafford","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0016","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000314","article-title":"Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: JFMC34-0601","volume":"3","author":"Ueno","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.clbc.2026.06.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/8866756","article-title":"Neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy in node-positive HR+\/HER2- breast cancer: a systematic review and meta-analysis","volume":"2024","author":"Vasigh","year":"2024","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2026.06.011_bib0019","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1245\/s10434-020-09073-6","article-title":"Axillary management after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer","volume":"28","author":"Kantor","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-020-00177-6","article-title":"Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer","volume":"6","author":"Kantor","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2026.06.011_bib0021","series-title":"Resource Guide Axillary Management for Patients with In-situ and Invasive Breast Cancer: A Concise Overview","year":"2026"},{"key":"10.1016\/j.clbc.2026.06.011_bib0022","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1245\/s10434-021-10385-4","article-title":"Surgical management of axilla following neoadjuvant endocrine therapy","volume":"28","author":"Murphy","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0023","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10549-023-06926-y","article-title":"Management of the axilla in postmenopausal patients with cN0 HR+\/HER2- breast cancer treated with neoadjuvant endocrine therapy","volume":"199","author":"Garcia-Tejedor","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.06.011_bib0024","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1245\/s10434-025-18697-5","article-title":"Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial","volume":"33","author":"Weiss","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0025","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1245\/s10434-022-12972-5","article-title":"Local-regional recurrence after neoadjuvant endocrine therapy: data from ACOSOG Z1031","volume":"30","author":"Hunt","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102085","article-title":"The Lucerne Toolbox 2 to optimise axillary management for early breast cancer","volume":"61","author":"Kaidar-Person","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clbc.2026.06.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf125","article-title":"BJS commission on the surgical management of the axilla in breast cancer","volume":"112","author":"Boland","year":"2025","journal-title":"Br J Surg"},{"key":"10.1016\/j.clbc.2026.06.011_bib0028","doi-asserted-by":"crossref","DOI":"10.1007\/s12609-026-00637-1","article-title":"Omission of axillary surgery in early-stage breast cancer: implications for multidisciplinary decision-making","volume":"18","author":"Grasso","year":"2026","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.clbc.2026.06.011_bib0029","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-026-07910-y","article-title":"Omission of axillary surgery in early breast cancer with negative lymph nodes: a systematic review and meta-analysis of randomized clinical trials","volume":"216","author":"Castelo","year":"2026","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.06.011_bib0030","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on axillary ultrasonography: the SOUND randomized clinical trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0031","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary surgery in breast cancer - primary results of the INSEMA trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.06.011_bib0032","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","article-title":"Omitting axillary dissection in breast cancer with sentinel-node metastases","volume":"390","author":"de Boniface","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.06.011_bib0033","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: ACOSOG Z1071","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2026.06.011_bib0034","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: SN FNAC","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0036","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy using selective evaluation of clipped nodes","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071565","article-title":"Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study","volume":"13","author":"Banys-Paluchowski","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.06.011_bib0038","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-018-3021-9","article-title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial","volume":"19","author":"Henke","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.clbc.2026.06.011_bib0039","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.breast.2023.02.006","article-title":"Regional radiotherapy after primary systemic treatment for cN+ breast cancer patients","volume":"68","author":"Boersma","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.06.011_bib0040","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of AMAROS","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0041","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1245\/s10434-019-07564-9","article-title":"Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma","volume":"26","author":"Thornton","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0042","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10549-011-1735-4","article-title":"Invasive lobular carcinoma: response to neoadjuvant letrozole therapy","volume":"130","author":"Dixon","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.06.011_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102669","article-title":"Neoadjuvant therapy in hormone receptor-positive\/HER2-negative breast cancer","volume":"123","author":"Cantini","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2026.06.011_bib0044","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/14737140.2024.2330601","article-title":"Neo-adjuvant therapies for ER-positive\/HER2-negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond","volume":"24","author":"Stravodimou","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clbc.2026.06.011_bib0045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0046","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/1078-0432.CCR-25-2435","article-title":"Neoadjuvant abemaciclib plus letrozole versus chemotherapy in patients with HR+\/HER2- highly proliferative breast cancer: the CARABELA trial","volume":"32","author":"Caballero","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.06.011_bib0047","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1016\/j.annonc.2025.08.725","article-title":"Risk of recurrence after neoadjuvant ribociclib plus endocrine therapy in clinically high-risk ER-positive\/HER2-negative breast cancer: preliminary analysis of the SOLTI-RIBOLARIS trial","volume":"36","author":"Cottu","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.06.011_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104743","article-title":"Ribociclib plus endocrine treatment versus standard-of-care chemotherapy in intermediate-risk HR-positive\/HER2-negative early breast cancer: results from the neoadjuvant cohort of the phase III WSG ADAPTcycle trial","volume":"10","author":"Harbeck","year":"2025","journal-title":"ESMO Open"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:30:46Z","timestamp":1786145446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1526820926000947"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.06.011","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axillary Management After Neoadjuvant Endocrine Therapy in HR-Positive\/HER2-Negative Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}